Prolyl hydroxylase domain
From Proteopedia
(Difference between revisions)
| Line 20: | Line 20: | ||
**[[6st3]] - hPHD2 catalytic domain + Mn + pyrimidin derivative<br /> | **[[6st3]] - hPHD2 catalytic domain + Mn + pyrimidin derivative<br /> | ||
**[[6yvt]] - hPHD2 catalytic domain + Mn + pyridin derivative<br /> | **[[6yvt]] - hPHD2 catalytic domain + Mn + pyridin derivative<br /> | ||
| - | **[[6qgv]], [[5a3u]] - hPHD2 catalytic domain + Mn + inhibitor<br /> | + | **[[6qgv]], [[5a3u]], [[6st3]], [[6yvt]], [[6zbn]], [[6zbo]] - hPHD2 catalytic domain + Mn + inhibitor<br /> |
**[[5ox6]], [[6ox5]] - hPHD2 catalytic domain + Mn + drug<br /> | **[[5ox6]], [[6ox5]] - hPHD2 catalytic domain + Mn + drug<br /> | ||
**[[5lat]], [[5lb6]], [[5lbb]], [[5lbc]], [[5lbe]], [[5lbf]], [[4uwd]] - hPHD2 catalytic domain (mutant) + Mn + quinolin derivative<br /> | **[[5lat]], [[5lb6]], [[5lbb]], [[5lbc]], [[5lbe]], [[5lbf]], [[4uwd]] - hPHD2 catalytic domain (mutant) + Mn + quinolin derivative<br /> | ||
| - | **[[ | + | **[[6yvx]], [[6yvz]] - hPHD2 catalytic domain + Mn + peptide<br /> |
| + | **[[6yw3]] - hPHD2 catalytic domain + Mn + peptide + oxalylglycine<br /> | ||
| + | **[[6yw1]], [[6yw2]], [[6yw4]] - hPHD2 catalytic domain (mutant) + Mn + peptide + oxalylglycine<br /> | ||
*Prolyl hydroxylase domain containing other metal ions | *Prolyl hydroxylase domain containing other metal ions | ||
| - | **[[2y33]] – hPHD2 catalytic domain residues | + | **[[2y33]] – hPHD2 catalytic domain residues + Zn + quinolin derivative – human<br /> |
| - | **[[3ouh]], [[3oui]], [[5v18]] - hPHD2 catalytic domain + Fe + inhibitor<br /> | + | **[[3ouh]], [[3oui]], [[5v18]], [[6nmq]], [[6yvw]], [[6yw0]] - hPHD2 catalytic domain + Fe + inhibitor<br /> |
**[[4kbz]] - hPHD2 catalytic domain (mutant) + Fe + inhibitor<br /> | **[[4kbz]] - hPHD2 catalytic domain (mutant) + Fe + inhibitor<br /> | ||
**[[4jzr]] - hPHD2 catalytic domain + Ni + inhibitor<br /> | **[[4jzr]] - hPHD2 catalytic domain + Ni + inhibitor<br /> | ||
Revision as of 11:00, 1 February 2022
| |||||||||||
3D Structures of prolyl hydroxylase domain
Updated on 01-February-2022
References
- ↑ Stolze IP, Mole DR, Ratcliffe PJ. Regulation of HIF: prolyl hydroxylases. Novartis Found Symp. 2006;272:15-25; discussion 25-36. PMID:16686427
- ↑ Rosen M D, Venkatesan H, Peltier H M, Bembenek S D, Kanelakis K C, Zhao L X, Leonard B E, Hocutt F M, Wu X, Palomino H L, Brondtetter T I, Haugh P V, Cagnon L, Yan W, Liotta L A, Young A, Mirzadegan T, Shankley N P, Barrett T D, Rabinowitz M H. Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues. ACS Medicinal Chemical Letters. 2010 Oct 5.
Created with the participation of Andrew Winslow.
